Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Rhea-AI Summary

Annovis (NYSE: ANVS) announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, 2026 (1:40–2:05 PM, Picasso 4&5).

The talk covers a multi-protein model of Alzheimer’s disease, arguing for targeting amyloid, tau, alpha-synuclein, TDP-43 and other aggregating proteins. The presentation includes a Q&A and highlights Annovis’ lead oral drug, buntanetap, now in a pivotal Phase 3 trial.

News Market Reaction – ANVS

-5.83%

-5.83% Session close to close

In the May 7 session, ANVS declined 5.83%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.8% in the session following this news. A negative reaction despite this largely s...

Analysis

The stock moved -5.8% in the session following this news. A negative reaction despite this largely scientific-focused announcement would fit a pattern where ANVS has sometimes traded lower following otherwise constructive updates, including clinical and financing news. Shares remain below the $2.66 200‑day MA and far under the 52‑week high of $5.50, reflecting prior dilution and mixed historical responses. Investors often revisit recent events such as the $10 million offering and prior data releases when reassessing risk around non-data catalysts.

Key Figures

Conference dates: May 12–14, 2026 Presentation date: May 13, 2026 Presentation time: 1:40 PM–2:05 PM +3 more

6 metrics

Conference dates May 12–14, 2026 Fierce Biotech Week 2026 schedule

Presentation date May 13, 2026 CEO scientific presentation on multi-protein AD model

Presentation time 1:40 PM–2:05 PM Scheduled conference session length

Biotech CEOs More than 100 Number of CEOs and founders attending conference

Participating companies Over 500 Companies represented at Fierce Biotech Week 2026

Pharma organizations 15 Top global pharmaceutical organizations represented

Historical Context

5 past events · Latest: Apr 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 28	Clinical data update	Positive	-2.1%	Phase 2/3 AD trial showed cognitive gains and biomarker reductions in pTau217-positive patients.
Apr 10	Financing and runway	Neutral	-1.9%	Closed $10M offering plus $1.5M board investment, extending cash runway through Q2 2027.
Apr 09	Dilutive equity offering	Negative	-29.6%	Announced $10M underwritten stock and warrant offering at $1.90 with $2.50 exercise price.
Apr 02	Patent issuance	Positive	+7.5%	Secured U.S. patent for buntanetap in neurological injuries from brain infections through 2044.
Mar 31	Profile-building review	Positive	+10.9%	Published historical review of buntanetap’s discovery and clinical progress in The Scientist.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows ANVS sometimes selling off on positive clinical or financing updates, while intellectual property and profile-building announcements have coincided with strong gains.

Recent Company History

Over the past months, Annovis highlighted multiple milestones around lead drug buntanetap, including a Nature NPJ Dementia publication showing dose-dependent cognitive benefits in 351 mild AD patients and biomarker improvements, and steady Phase 3 enrollment progress. The company executed a $10 million equity offering with warrants and later confirmed runway extension through Q2 2027. A new U.S. patent running to 2044 and a historical review in The Scientist underscored buntanetap’s clinical and IP positioning, setting the backdrop for today’s scientific-focused conference presentation.

Key Terms

phase 3, neurodegenerative, amyloid, tau, +3 more

7 terms

phase 3 medical

"a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

neurodegenerative medical

"buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD)"

Neurodegenerative describes diseases where nerve cells in the brain or spinal cord progressively lose function and die, causing worsening movement, memory or other mental abilities over time. For investors this matters because such conditions create large, long-term needs for therapies and caregiving; developing treatments often requires lengthy, expensive research and regulatory testing but can lead to substantial, sustained market opportunities if a therapy proves effective — like fixing the wiring in a whole neighborhood rather than a single house.

amyloid medical

"including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression"

Amyloid are abnormal protein clumps that form when normally soluble proteins misfold and stick together, accumulating in organs or the brain much like lint building up in a clogged filter. They matter to investors because amyloid deposits are central to several serious diseases and are common targets for diagnostics, therapies and regulatory review; progress or setbacks in amyloid-related tests and drugs can strongly affect biotech valuations and clinical-stage company prospects.

tau medical

"including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression"

Tau is a protein found in brain cells that helps stabilize their internal skeleton; when it misfolds and clumps it is linked to nerve cell damage and memory loss seen in disorders like Alzheimer’s. Investors watch tau because drugs or tests that reduce, prevent, or measure its harmful forms can change the outlook for companies and the size of potential markets, much like a new diagnostic tool or repair kit can reshape demand in any industry.

alpha-synuclein medical

"including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression"

A small brain protein that helps nerve cells function, which can misfold and clump together in certain neurodegenerative diseases. Investors care because these clumps are both a target for new therapies and a potential marker used in clinical trials and diagnostics; success or failure of drugs aimed at alpha-synuclein can strongly affect a developer’s clinical prospects, regulatory chances, and market value. Think of it as a faulty part in a machine that companies try to repair or remove.

tdp-43 medical

"including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression"

TDP-43 is a protein inside cells that helps regulate how genetic instructions are used; when it misfolds or accumulates into clumps in brain or spinal cord cells, it is linked to neurodegenerative conditions like ALS and some dementias. For investors, TDP-43 matters because it is a clear biological target for diagnostics and therapies—detecting or stopping its abnormal behavior could change patient care and create commercial value, similar to fixing a faulty part in a complex machine.

biomarker medical

"meaningful clinical benefits supported by encouraging biomarker data, and is now in a"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026.

Presentation Details:

• Title: "The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept"
• Presenter: Maria Maccecchini, Ph.D., President and CEO
• Date: Wednesday, May 13, 2026
• Time: 1:40 PM - 2:05 PM
• Location: Picasso 4&5
  

The presentation will trace the scientific foundation for understanding AD as a disease driven by multiple neurotoxic aggregating proteins and examine the historical gap between that evidence and the field's reliance on a single-protein approach. Dr. Maccecchini will make the case supporting the importance of the full spectrum of neurotoxic proteins – including amyloid, tau, alpha-synuclein, TDP-43, and more – in disease progression, which are not only backed by decades of scientific data but also represent a promising path forward for the AD drug development.

"Alzheimer's disease has never been a one-protein problem, and overreliance on amyloid as the sole driver of the disease has come at a cost, hindering progress for alternative therapeutic candidates," said Maria Maccecchini, Ph.D., President and CEO. "Annovis’ program is built exactly on the premise that simultaneous reduction of the overexpression of several aggregating proteins interrupts the toxic cascade and improves the health of nerve cells. Our lead drug buntanetap, a translational inhibitor of these proteins, has already shown meaningful clinical benefits supported by encouraging biomarker data, and is now in a pivotal Phase 3 clinical trial."

The presentation will be followed by a Q&A discussion and is open to all participants.

Fierce Biotech Week 2026 brings together leaders across R&D, clinical development, business development, and communications to confront the industry's most pressing challenges, from capital strategy and pipeline advancement to partnership formation and commercialization. With more than 100 biotech CEOs and founders, over 500 companies, and 15 top global pharmaceutical organizations represented, the event is built for the leaders driving consequential decisions.

About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com

Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com

FAQ

When will Annovis (ANVS) present at Fierce Biotech Week 2026?

Annovis will present on May 13, 2026, 1:40–2:05 PM. According to the company, Maria Maccecchini, Ph.D., will deliver the presentation in Picasso 4&5 followed by a Q&A open to conference participants.

What topic will Annovis CEO Maria Maccecchini cover at Fierce Biotech Week 2026?

She will present on the multi-protein reality of Alzheimer’s disease. According to the company, the talk argues that amyloid, tau, alpha-synuclein, TDP-43 and other proteins jointly drive disease and warrant multi-target strategies.

Does the Annovis presentation mention the company’s lead drug buntanetap (ANVS)?

Yes. According to the company, the presentation references buntanetap and notes it is a translational inhibitor now in a pivotal Phase 3 clinical trial, with supporting biomarker data and reported clinical benefits in earlier studies.

Where and how long is the Annovis (ANVS) presentation at Fierce Biotech Week 2026?

The presentation is scheduled for 25 minutes on May 13, 2026, at Picasso 4&5. According to the company, it includes a focused talk followed by a live Q&A session open to attendees.

Will the Annovis Fierce Biotech Week presentation include audience Q&A?

Yes. According to the company, the presentation will be followed by a Q&A discussion that is open to all participants, allowing attendees to ask questions about the multi-protein AD model and buntanetap.

How does Annovis describe the scientific rationale presented at Fierce Biotech Week 2026?

Annovis describes the rationale as evidence that Alzheimer’s involves multiple neurotoxic aggregating proteins. According to the company, decades of research support targeting a spectrum of proteins rather than a single-protein approach.